Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.21 USD | +2.98% | +3.42% | +36.52% |
Jun. 04 | Top Premarket Gainers | MT |
Jun. 03 | FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Most analysts recommend that the stock should be sold or reduced.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+36.52% | 120M | B- | ||
+55.70% | 59.34B | B- | ||
+42.89% | 40.24B | A | ||
-5.39% | 39.88B | B | ||
-5.56% | 28.55B | C | ||
+16.46% | 27.26B | B- | ||
-20.56% | 19.23B | B | ||
+33.03% | 12.61B | C+ | ||
+2.72% | 12.49B | B+ | ||
+25.85% | 12.28B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FGEN Stock
- Ratings FibroGen, Inc.